Microbot Medical (NASDAQ:MBOT) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Microbot Medical (NASDAQ:MBOT) from a sell rating to a strong sell rating in a research report report published on Saturday.

MBOT has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a research report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th. Finally, B. Riley Financial assumed coverage on shares of Microbot Medical in a research report on Tuesday, February 10th. They issued a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Microbot Medical currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Microbot Medical Price Performance

NASDAQ:MBOT opened at $2.10 on Friday. The firm has a 50-day moving average of $2.41 and a 200-day moving average of $2.24. The company has a market cap of $141.04 million, a PE ratio of -7.24 and a beta of 1.06. Microbot Medical has a one year low of $1.60 and a one year high of $4.67.

Microbot Medical (NASDAQ:MBOT) last posted its earnings results on Sunday, March 22nd. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. On average, equities research analysts expect that Microbot Medical will post -0.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Microbot Medical

Institutional investors have recently added to or reduced their stakes in the company. Cornerstone Advisory LLC bought a new stake in Microbot Medical in the 3rd quarter worth about $30,000. American Century Companies Inc. bought a new stake in Microbot Medical in the 2nd quarter worth about $32,000. Zacks Investment Management bought a new stake in Microbot Medical in the 3rd quarter worth about $33,000. Man Group plc bought a new stake in Microbot Medical in the 4th quarter worth about $35,000. Finally, Squarepoint Ops LLC bought a new stake in Microbot Medical in the 3rd quarter worth about $37,000. 16.30% of the stock is owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.